{"DataElement":{"publicId":"3158828","version":"1","preferredName":"Person Prior Treatment Regimen Phase 0 Trial Complete Clinical Trial Eligibility Criteria Ind-3b","preferredDefinition":"an indicator that can have a value of yes, no, or not applicable related to a person having completed a prior therapy regimen as part of a phase 0 clinical trial, a clinical trial that uses an investigational agent that is available only in very limited quantities and which has never previously given to humans or for which there is extremely limited human experience, as an element of a personal medical history which are necessary to allow an individual to participate in a specific clinical trial.","longName":"3158827v1.0:2018259v1.0","context":"CTEP","contextVersion":"2.31","DataElementConcept":{"publicId":"3158827","version":"1","preferredName":"Person Prior Treatment Regimen Phase 0 Trial Complete Clinical Trial Eligibility Criteria","preferredDefinition":"information related to a person having completed a prior therapy regimen as part of a phase 0 clinical trial, a clinical trial that uses an investigational agent that is available only in very limited quantities and which has never previously given to humans or for which there is extremely limited human experience, as an element of a personal medical history which are necessary to allow an individual to participate in a specific clinical trial.","longName":"2236731v1.0:3158825v1.0","context":"CTEP","contextVersion":"2.31","ObjectClass":{"publicId":"2236731","version":"1","preferredName":"Person","preferredDefinition":"A human being.","longName":"C25190","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Person","conceptCode":"C25190","definition":"A human being.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":"NCI Thesaurus","workflowStatus":"RELEASED","registrationStatus":"Application","id":"F9FC6DF7-66EB-4CAB-E034-0003BA3F9857","latestVersionIndicator":"Yes","beginDate":"2005-06-20","endDate":null,"createdBy":"UMLLOADER_MAGE","dateCreated":"2005-06-20","modifiedBy":"SBREXT","dateModified":"2007-11-07","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"Property":{"publicId":"3158825","version":"1","preferredName":"Prior Treatment Regimen Phase 0 Trial Complete Clinical Trial Eligibility Criteria","preferredDefinition":"Earlier in time or order.:A treatment plan that specifies the dosage, the schedule, and the duration of treatment.:A clinical trial that uses an investigational agent that is available only in very limited quantities and which has never previously given to humans or for which there is extremely limited human experience. Phase 0 clinical trials are intended to enable researchers to understand the path of the drug in the body and its efficacy. Adverse event reporting in Phase 0 trials is expedited.  :To possess every necessary or normal part or component or step; having come or been brought to a conclusion.:Elements of a personal medical history which are necessary to allow an individual to participate in a specific clinical trial.","longName":"3158825v1.0","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Prior","conceptCode":"C25629","definition":"Earlier in time or order.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"No","displayOrder":"4"},{"longName":"Treatment Regimen","conceptCode":"C15697","definition":"A treatment plan that specifies the dosage, the schedule, and the duration of treatment.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"No","displayOrder":"3"},{"longName":"Phase 0 Trial","conceptCode":"C54721","definition":"A clinical trial that uses an investigational agent that is available only in very limited quantities and which has never previously given to humans or for which there is extremely limited human experience. Phase 0 clinical trials are intended to enable researchers to understand the path of the drug in the body and its efficacy. Adverse event reporting in Phase 0 trials is expedited.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"No","displayOrder":"2"},{"longName":"Complete","conceptCode":"C25250","definition":"To possess every necessary or normal part or component or step; having come or been brought to a conclusion.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"No","displayOrder":"1"},{"longName":"Clinical Trial Eligibility Criteria","conceptCode":"C16112","definition":"Characteristics which are necessary to allow a subject to participate in a clinical study, as outlined in the study protocol. The concept covers inclusion and exclusion criteria.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"94DD4C9F-D102-E260-E040-BB89AD4364AF","latestVersionIndicator":"Yes","beginDate":"2010-11-12","endDate":null,"createdBy":"CAMPBELB","dateCreated":"2010-11-12","modifiedBy":"ONEDATA","dateModified":"2010-11-12","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"ConceptualDomain":{"publicId":"2008538","version":"1","preferredName":"Therapies","preferredDefinition":"actions or administration of therapeutic agents to produce an effect that is intended to alter the course of a pathologic process (NCI).","longName":"TX","context":"CTEP","contextVersion":"2.31","origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"B214D04D-9F05-1CA5-E034-0003BA12F5E7","latestVersionIndicator":"Yes","beginDate":"2002-12-18","endDate":null,"createdBy":"MSUPLEY","dateCreated":"2002-12-18","modifiedBy":"SBR","dateModified":"2003-10-29","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"94DD4C9F-D113-E260-E040-BB89AD4364AF","latestVersionIndicator":"Yes","beginDate":"2010-11-12","endDate":null,"createdBy":"CAMPBELB","dateCreated":"2010-11-12","modifiedBy":"SBR","dateModified":"2016-06-06","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"ValueDomain":{"publicId":"3170966","version":"1","preferredName":"Eligibility Ind-3b","preferredDefinition":"A response or indicator that can have a value of yes, no, or not applicable.","longName":"3170966v1.0","context":"CTEP","contextVersion":"2.31","type":"Enumerated","dataType":"CHARACTER","minLength":null,"maxLength":"10","minValue":null,"maxValue":null,"decimalPlace":null,"PermissibleValues":[{"value":"Yes","valueDescription":"Yes","ValueMeaning":{"publicId":"2560453","version":"1","preferredName":"Yes","longName":"2560453","preferredDefinition":"The affirmative response to a question or activity.","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Yes","conceptCode":"C49488","definition":"The affirmative response to a question.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"2509CE87-B932-5C23-E044-0003BA3F9857","latestVersionIndicator":"Yes","beginDate":"2002-02-13","endDate":null,"createdBy":"SBR","dateCreated":"2002-02-13","modifiedBy":"CLOHNES","dateModified":"2023-09-26","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"97CE1289-7858-BF60-E040-BB89AD437833","beginDate":"2010-12-19","endDate":null,"createdBy":"ALAIS","dateCreated":"2010-12-19","modifiedBy":"ONEDATA","dateModified":"2010-12-19","deletedIndicator":"No"},{"value":"No","valueDescription":"No","ValueMeaning":{"publicId":"2559515","version":"1","preferredName":"No","longName":"2559515","preferredDefinition":"The non-affirmative response to a question.","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"No","conceptCode":"C49487","definition":"The non-affirmative response to a question.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"2509CE87-B588-5C23-E044-0003BA3F9857","latestVersionIndicator":"Yes","beginDate":"2002-02-13","endDate":null,"createdBy":"SBR","dateCreated":"2002-02-13","modifiedBy":"GDEEN","dateModified":"2024-01-02","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"97CE1289-7862-BF60-E040-BB89AD437833","beginDate":"2010-12-19","endDate":null,"createdBy":"ALAIS","dateCreated":"2010-12-19","modifiedBy":"ONEDATA","dateModified":"2010-12-19","deletedIndicator":"No"},{"value":"NA","valueDescription":"Not Applicable","ValueMeaning":{"publicId":"3170967","version":"1","preferredName":"Not Applicable","longName":"3170967","preferredDefinition":"Determination that a value is not relevant in the current context.","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Not Applicable","conceptCode":"C48660","definition":"Determination of a value is not relevant in the current context.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"97CE1289-786C-BF60-E040-BB89AD437833","latestVersionIndicator":"Yes","beginDate":"2010-12-19","endDate":null,"createdBy":"ALAIS","dateCreated":"2010-12-19","modifiedBy":"SBR","dateModified":"2018-01-19","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"97CE1289-7884-BF60-E040-BB89AD437833","beginDate":"2010-12-19","endDate":null,"createdBy":"ALAIS","dateCreated":"2010-12-19","modifiedBy":"ONEDATA","dateModified":"2010-12-19","deletedIndicator":"No"}],"ConceptualDomain":{"publicId":"2008525","version":"1","preferredName":"Eligibility","preferredDefinition":"trial-specific criteria that a patient must meet to be enrolled.","longName":"ELIG","context":"CTEP","contextVersion":"2.31","origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"B1EC3968-9F25-305A-E034-0003BA12F5E7","latestVersionIndicator":"Yes","beginDate":"2002-12-16","endDate":null,"createdBy":"MSUPLEY","dateCreated":"2002-12-16","modifiedBy":"SBR","dateModified":"2003-10-29","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"RepresentationTerm":{"publicId":"2694966","version":"1","preferredName":"Ind-3b","preferredDefinition":"A response or indicator that can have a value of yes, no, or not applicable.","longName":"C49797","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Yes, No, or Not Applicable Response","conceptCode":"C49797","definition":"A response or indicator that can have a value of yes, no, or not applicable.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":"NCI Thesaurus","workflowStatus":"RETIRED ARCHIVED","registrationStatus":"Retired","id":"3EBCA780-282F-4411-E044-0003BA3F9857","latestVersionIndicator":"Yes","beginDate":"2007-11-12","endDate":"2016-04-27","createdBy":"CURTIST","dateCreated":"2007-11-12","modifiedBy":"TAYLORT","dateModified":"2020-10-02","changeDescription":"10.2.20 TL changed WFS from RETIRED PHASED OUT to RETIRED ARCHIVED. Retired DBW 04-27-2016 per Tina Taylor approved by Dianne Reves","administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"97CE1289-7843-BF60-E040-BB89AD437833","latestVersionIndicator":"Yes","beginDate":"2010-12-19","endDate":null,"createdBy":"ALAIS","dateCreated":"2010-12-19","modifiedBy":"REEVESD","dateModified":"2012-04-26","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"ClassificationSchemes":[],"AlternateNames":[],"ReferenceDocuments":[{"name":"At least 2 weeks since prior","type":"Preferred Question Text","description":"At least 2 weeks since prior investigational agent administered as part of a Phase 0 study, and associated toxicities resolved to eligibility levels.","url":null,"context":"CTEP"},{"name":"CRF Text 2","type":"Alternate Question Text","description":"Has the patient been treated with an investigational agent within the past 4 weeks prior to the anticipated Cycle 1, Day 1 (or within five half-lives of the investigational agent, whichever is longer)","url":null,"context":"CTEP"},{"name":"CRF Text 3","type":"Alternate Question Text","description":"Has the patient been treated with any other investigational agent within the past 4 weeks prior to the anticipated Cycle 1, Day 1?","url":null,"context":"CTEP"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Qualified","id":"94DD4C9F-D124-E260-E040-BB89AD4364AF","latestVersionIndicator":"Yes","beginDate":"2010-11-12","endDate":null,"createdBy":"CAMPBELB","dateCreated":"2010-11-12","modifiedBy":"SARAHB","dateModified":"2017-06-05","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"}}